Mounjaro
tirzepatide · Injection once a week
A once-weekly injection that acts on both GIP and GLP-1 receptors. Licensed in the UK for weight management alongside diet and physical activity.
Mounjaro guide
Jabs
The injectable medicines used for weight management in the UK all act on the GLP-1 receptor, which helps regulate appetite and slows how quickly the stomach empties. Mounjaro (tirzepatide) also acts on the GIP receptor. They are used alongside a reduced-calorie diet and increased physical activity, not instead of them.
tirzepatide · Injection once a week
A once-weekly injection that acts on both GIP and GLP-1 receptors. Licensed in the UK for weight management alongside diet and physical activity.
Mounjaro guide
semaglutide · Injection once a week
A once-weekly semaglutide injection licensed in the UK for weight management and, in some patients, to reduce cardiovascular risk.
Wegovy guide
liraglutide · Injection once a day
An older, once-daily GLP-1 injection for weight management. Branded Saxenda has reportedly been discontinued in the UK, with generic liraglutide available; check current branded availability with your pharmacist or prescriber.
Liraglutide (Saxenda / generic) guide
| Attribute | Mounjaro | Wegovy | Liraglutide (Saxenda / generic) |
|---|---|---|---|
| Active ingredient | tirzepatide | semaglutide | liraglutide |
| Drug class | GIP/GLP-1 receptor agonist | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Manufacturer | Eli Lilly | Novo Nordisk | Novo Nordisk (Saxenda); generic liraglutide from other manufacturers |
| Form | Injection | Injection | Injection |
| How often | once a week | once a week | once a day |
| Device | KwikPen (multi-dose pre-filled pen) | FlexTouch pen | Pre-filled pen |
| Starting dose | 2.5mg | 0.25mg | 0.6mg |
| Dose range | 2.5mg to 15mg | 0.25mg to 7.2mg | 0.6mg to 3mg |
| UK status | Licensed in the UK for weight management | Licensed in the UK for weight management | Licensed in the UK for weight management |
| NICE guidance | NICE TA1026 (December 2024) | NICE TA875 (March 2023) | NICE TA664 (December 2020) |
| Common side effects | Nausea, Diarrhoea, Constipation, Vomiting, Indigestion and reflux, Injection site reactions | Nausea, Diarrhoea, Constipation, Vomiting, Indigestion and reflux, Injection site reactions | Nausea, Diarrhoea, Constipation, Vomiting, Headache, Injection site reactions |